On August 8, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the second quarter of 2024 and provided a business update. The company recently announced that the Phase 2a clinical trial of IMC-2 (valacycovir+celecoxib) has completed enrollment and we anticipate topline results from the trial in October 2024. Ongoing blinded safety analysis of the Phase 2a study indicates that study drug has been well tolerated with no serious adverse events reported. The company is planning to utilize the results from the Phase 2a study in the design of a Phase 2b clinical trial of IMC-2 in Long COVID. Following a $1.7 million public offering in May 2024, the company now has an operational runway into the first quarter of 2025.
